| Title |
Reply to Comment on ‘Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis”
|
|---|---|
| Published in |
British Journal of Cancer, August 2018
|
| DOI | 10.1038/s41416-018-0226-3 |
| Pubmed ID | |
| Authors |
Helen Curtis, Ben Goldacre |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2018.
All research outputs
#4,243,742
of 23,100,534 outputs
Outputs from British Journal of Cancer
#2,810
of 10,510 outputs
Outputs of similar age
#82,786
of 333,760 outputs
Outputs of similar age from British Journal of Cancer
#46
of 71 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,510 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,760 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.